The COPERNICUS study of amivantamab/lazertinib showed lower rates of adverse events and discontinuation with supportive care regimens in patients with EGFR-mutated non–small cell lung cancer.
|Videos|May 30, 2017
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Treatment of EGFR Mutant Non-Small Cell Lung Cancer
Advertisement
- 65-year-old male, former smoker (25 pack-years, quit 12 years ago) presented complaining of persistent lower back pain, extreme fatigue, shortness of breath, and a 25-lb weight loss in the past 6 months.
- PMH includes rheumatoid arthritis which significantly limits his physical activity.
- Back pain also limited the patient’s daily activity.
- MRI of the spine showed evidence of multiple lesions, but none were causing cord compression.
- CT of the chest showed a 4-cm mass in the left lung, with enlarged bilateral mediastinal lymph nodes.
- The MRI of the brain revealed no metastases.
- ECOG PS was assessed to be 2.
- He underwent an endobronchial ultrasound-directed biopsy of the mediastinal lymph nodes.
- Pathology revealed poorly differentiated adenocarcinoma.
- Molecular testing showed a mutation in EGFR exon19 deletion.
Advertisement
Related to this article
Updated TRUST-I and TRUST-II data show durable taletrectinib responses in ROS1+ NSCLC regardless of prior chemotherapy or fusion partner.
The FDA approved an sNDA updating the taletrectinib label with a 49.7-month median duration of response from TRUST-I in ROS1-positive NSCLC.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
David DiBardino, MD, explains how intratumoral radioenhancer therapy works, why standardization remains a challenge, and what early CONVERGE study data suggest for locally advanced NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
SOT106 Receives New FDA FTD and ODD in Sarcoma
2
Iberdomide Doubles MRD-Negative CR Rate in Phase 3 EXCALIBER-RRMM Trial
3
IMS 2026 Day 4 Recap: MRD-Guided Regimens Highlight Final Sessions
4
Trispecifics: A New Strategy to Prevent Antigen Escape
5